QNCX Latest Press Releases

-- March 30, 2026 --

Quince Therapeutics Settles Approximately $16.4 Million of Debt Business Wire 8:30 AM

-- February 9, 2026 --

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives Business Wire 4:05 PM

-- January 29, 2026 --

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia Business Wire 3:10 PM

-- January 28, 2026 --

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting Business Wire 4:05 PM

-- December 15, 2025 --

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia Business Wire 8:00 AM

-- December 10, 2025 --

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders Business Wire 4:05 PM

-- November 24, 2025 --

Quince Therapeutics to Participate at Investor Events in December 2025 Business Wire 8:00 AM

-- November 12, 2025 --

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Business Wire 4:05 PM

-- November 10, 2025 --

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software